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Abstract
Data regarding kidney transplantation (KT) and dialysis outcomes are rare in Asian populations. In the present study, we evaluated the
clinical outcomes associated with KT using claims data from the Korean national public health insurance program. Among the 35,418
adult patients with incident dialysis treated between 2005 and 2008 in Korea, 1539 underwent KT. An optimal balanced risk set
matching was attempted to compare the transplant group with the control group in terms of the overall survival and major adverse
cardiac event–free survival. Before matching, the dialysis group was older and hadmore comorbidities. After matching, there were no
differences in age, sex, dialysis modalities, or comorbidities. Patient survival was significantly better in the transplant group than in the
matched control group (P<0.001). In addition, the transplant group showed better major adverse cardiac event–free survival than
the dialysis group (P<0.001; hazard ratio, 0.49; 95% confidence interval, 0.32–0.75). Korean patients with incident dialysis who
underwent long-term dialysis had significantly more cardiovascular events and higher all-cause mortality rates than those who
underwent KT. Thus, KT should be more actively recommended in Korean populations.
Abbreviations: CCI = Charlson Comorbidity Index, CHF = congestive heart failure, CI = confidence interval, COPD = chronic
obstructive pulmonary disease, CRC = Clinical Research Center, CVD = cerebrovascular disease, DM = diabetes mellitus, ESRD =
end-stage renal disease, HD = hemodialysis, HIRA = Korea Health Insurance Review and Assessment Service, HR = hazard ratio,
HSS = health security system, KONOS = Korean Network for Organ Sharing, KT = kidney transplantation, KTR = kidney transplant
recipient, MACE = major adverse cardiac event, MI = myocardial infarction, NHI = National Health Insurance, OBM = optimal
balanced risk set matching, PD = peritoneal dialysis, PSM = propensity score matching, PVD = peripheral vascular disease, SES =
socioeconomic status.
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End-stage renal disease (ESRD) increases the incidence of
comorbidities and the mortality rate, which are difficult to
prevent.[1] However, despite interest in the burden of this disease,
the incidence of ESRD is steadily increasing annually.[2,3] Kidney
transplantation (KT) is the best treatment for patients with ESRD
in terms of increasing the survival rate, reducing complications,
and improving quality of life.[4–6] The degree of clinical benefit
associated with KT has recently become important.[7] In Asia,
however, there are insufficient data regarding KT and dialysis
outcomes. The benefit of KT differs according to sociocultural,
racial, and health insurance coverage factors.[8] Therefore, ethnic
differences should be considered because they can affect clinical
KT outcomes.[8] Thus, investigations into KT versus dialysis
outcomes in Asian populations remain important.
Cardiovascular disease is a leading cause of mortality in
patients with ESRD, even among those undergoing transplanta-
tion.[9,10] The long-term use of immunosuppressive agents may
induce hypertension, diabetes, and dyslipidemia.[11] Thus, there
are several concerns regarding whether KT can achieve a
reduction in cardiovascular events.[12] Moreover, emerging
evidence regarding racial differences in the cardiovascular
outcomes of KT recipients cannot be explained by traditional
risk factors alone, even among the Asian population.[13,14]
Therefore, the effect of KT on cardiovascular outcomes remains
to be clarified, especially in Asian recipients.
A national population-based cohort study used data from the
Korea Health Insurance Review and Assessment Service (HIRA).
This cohort is a complete enumeration survey of the entire
population of Korea because all citizens are mandatorily covered
by the government-initiated public health insurance program[15];
therefore, using this cohort should allow for more representative
transplant outcomes of Asians, eliminating any potential
environmental, socioeconomic, and racial differences. Using this
cohort, we recently reported that the overall mortality rate of
patients with incident peritoneal dialysis (PD) was consistently
higher than that of patients on hemodialysis (HD).[16]
There have been several methodological issues about compar-
ing maintenance dialysis and KT in terms of patients requiring
renal replacement therapy.[7] In the present study, we aimed to
investigate data for all-cause mortality and cardiovascular
outcomes between KT patients and patients on dialysis using
an optimal balanced risk set matching (OBM) analysis of a
national population-based cohort in South Korea. We attempted
to resolve the methodological concerns about maintenance
dialysis versus undergoing transplant in terms of clinical
outcomes using a newly developed matching method.2. Materials and methods
2.1. Data source and study participants
In Korea, the National Health Security System (HSS) is a
mandatory social insurance program; it is composed of the
National Health Insurance (NHI) and Medical Aid and is
overseen by the Ministry of Health and Welfare. Under this
system, all data are stored and managed in the National Health
Insurance Claims Database, which contains all the information
about reimbursements under the fee-for-service system (NHI) or
per diem system (Medical Aid) for patients on dialysis.[17,18]
Using the national population-based cohort from the Korea
HIRA, we obtained data for all patients who underwent KT and
those who underwent incident dialysis between January 1, 2005,2
and December 31, 2008, in Korea. These data recently became an
open-access research resource to help Korean researchers
perform comprehensive public health studies on patients on
dialysis.[16,19,20]
Briefly, KT was identified by the occurrence of a claim for the
payment code R3280.[15,16] Themethods used to identify patients
on dialysis and their comorbidities using the HIRA database have
been described previously.[16,19] Comorbidities were identified by
reviewing patients’ medical history during the year before the
initiation of dialysis therapy. We excluded 2772 patients who
survived for <90 days from the date of dialysis initiation (Fig. 1).
The present study was performed in accordance with the Helsinki
Declaration and was approved by the institutional review board
of Seoul National University Hospital (no.: 1407-146-597).
2.2. Outcomes
The primary outcome was the cumulative overall survival rate
during the observation period. The secondary outcome of this
study was the occurrence of major adverse cardiac events
(MACE) during the follow-up, which was defined as a composite
of the incidence of nonfatal myocardial infarction (MI),
hemorrhagic and ischemic stroke, and coronary artery bypass
graft surgery or percutaneous coronary intervention.2.3. Statistical analysis
In this study, we considered 2 methods for analysis to compare 2
groups to account for the fact that patients with ESRD switched
from the dialysis group to the transplantation group during the
follow-up, and patients with ESRD had different baseline
characteristics between the transplant and dialysis groups. If
patients with ESRD at the time of kidney transplant were directly
compared to patients with ESRD on dialysis, the time to the
dialysis exposure status among patients who received a kidney
transplant would not be addressed. The term “immortal time
bias” has been used to describe this circumstance.[21] One of the
proper ways to account for this matter is to use a time-dependent
hazard model. It considers the time-varying nature of the
exposure status and minimizes the possibility of immortal time
bias from time-varying exposures.[5,21]
The other issue is adjusting the baseline characteristics between
the treatment and control groups. Observational studies are a
yieldingway of assessing treatment effects in a general population
with low cost. However, observational studies could not select
the patient and control group under restricted clinical supervi-
sion, so they may cause lack of a control group. These limitations
may lead to potential bias. Propensity score matching (PSM) is
one of the popular methods to solve this issue. However, with
conventional PSM, the control group should be matched only
with patients who do not receive a transplant; therefore, it is
possible that the groups will not be similar with respect to the
relevant prognostic factors for comparison with kidney trans-
plant recipients (KTRs). For example, transplant candidates are
generally considered to have fewer risk characteristics than
patients undergoing maintenance dialysis. Therefore, conven-
tional matching would overestimate the survival advantage
associated with receiving a kidney transplant.
Thus, we accounted for these 2 issues by using the time-
dependent PSMmethod, that is, OBM. This method considers the
time-dependent exposure and balances covariates of the 2
groups.[22–24] The time-dependent propensity score is computed
for each patient using the treatment hazard, and each treated
Figure 1. Study flowchart. HD = hemodialysis, HIRA = Korea Health Insurance Review and Assessment Service, KT = kidney transplantation, PD = peritoneal
dialysis.
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treated patient with a similar propensity score. More details
about the estimation of the propensity score using a Cox
proportional model are described in previous reports.[22–24]
The major differences between risk set matching and
conventional matching are the following: risk set matching uses
the risk of receiving treatment, which is related to the Cox hazard
model. The time-varying hazard of treatment works like the
propensity score. Second, in risk set matching, a patient treated at
time Ti is matched to a patient not yet treated at time Ti rather
than to a patient who never received a transplant. This means that
a patient who undergoes transplantation at time Ti can enter the
study as a treated patient or as a not-yet-treated control for the
other transplant patient prior to time Ti.
We included patients’ characteristics such as age, sex, and the
dialysis modality; the HSS, which is composed of the NHI and
Medical Aid data; comorbidities such as diabetes mellitus (DM),
MI, congestive heart failure (CHF), peripheral vascular disease
(PVD), cerebrovascular disease (CVD), chronic obstructive
pulmonary disease (COPD), peptic ulcer disease, liver disease,
and any cancer; and the Charlson Comorbidity Index (CCI) to
estimate the time-dependent propensity score.[25] Matching was
performed for each of the risk sets. When there was 1 treated
patient or multiple treated patients in the risk set, controls who
were closest in terms of the time-dependent propensity score were
chosen. The matched subjects were removed from the next risk
sets. The same process continued and was repeated with the next
risk set. The matching process stopped when there were no more
treated patients in the risk set. Our methods were easy to
implement in R, and the code is presented in Supplementary
Table 1, http://links.lww.com/MD/B200.3
In the present study, continuous and categorical variables were
compared between the transplant and control groups using the t
test and x2 test, respectively. Standardized differences were also
used to compare baseline characteristics between the 2 groups
before and after OBM.[26]
Kaplan–Meier survival curves were estimated for the trans-
plant and control groups after OBM. The Peto and Peto
modification of the Gehan–Wilcoxon test was used to compare
the Kaplan–Meier survival curves from the matched dataset.
For the multivariate hazard model, we did not include CCI as
an adjusting covariate because multicollinearity issues arise when
too many variables are added to the model. We performed a
stratified subgroup analysis by age (18–39, 40–49, 50–59, >60
years), sex, HSS, the dialysis type, and 9 comorbidities (DM, MI,
CHF, PVD, CVD, COPD, peptic ulcer disease, liver disease, and
any cancer). Subgroup analyses were used to evaluate the
consistency of treatment across multiple groups. We performed
an interaction test to confirm the modifying effects of each
variable. However, the results of the subgroup analyses may need
to be interpreted with caution because of the potential type 1
error that can occur with multiple comparisons.[27–30] All of the
statistical analyses were conducted using SAS (version 9.3; SAS
Institute, Inc, Cary, NC) and R version 2.14 for Windows (http://
cran.r-project.org/). PSM was performed using the optmatch
package in R.[31]2.4. Sensitivity analysis
Our data do not include KT waiting-list information and could
not separate the deceased donor KTRs from the living donor
KTRs because the HIRA data do not include information about
Yoo et al. Medicine (2016) 95:33 Medicinethe donor type. The comparison of the clinical outcomes of
transplant recipients with those of patients in the transplant
waiting list has been considered appropriate.[5,9] There are
several reasons why previous studies did not compare the
transplant group with an all ESRD patient group. One of the
main reasons is the biased predictions. If all patients with ESRD
are set as the control group to the transplant treatment group,
positive effects of transplantation may be overestimated.[5,9]
To overcome this limitation, we conducted several additional
analyses. We used the Korean Network for Organ Sharing
(KONOS) data for these analyses.[17] First, we compared the
survival between living donor kidney transplant, deceased donor
kidney transplant, and KT wait-listed patients in the KONOS
data. Second, we compared the survival results between the wait-
listed patients in the KONOS data and the matched control
patients in the HIRA data. The purpose of the sensitivity analysis
was to match the baseline characteristics of the matched control
group (who did not undergo transplantation) from the HIRA
data to those of the KTwait-listed patients from the KONOS data
in Korean patients with ESRD.[17] Furthermore, we conducted
analyses using the Clinical Research Center (CRC) for ESRD
(NCT00931970) database to resolve the validity ofMACE of the
matched control group in our study cohort.3. Results
3.1. Baseline characteristics of the study population
before and after optimal balanced risk set matching
Patients’ baseline characteristics were compared between the
transplant and dialysis groups. In total, 1539 subjects undergoing
KT between 2005 and 2008 were included in the transplant
group (Table 1).Table 1








Age, y 57.9 (13.8) 41.8 (10.9) <0.001
Sex (female) 12,876 (41.4) 603 (39.2) 0.09
Dialysis modality (ITT) 0.033
PD 7,514 (24.2) 409 (26.6)
HD 23,593 (75.8) 1,130 (73.4)
Health security system <0.001
National Health Insurance 26,746 (86.0) 1,452 (94.3)
Medical Aid 4,361 (14.0) 87 (5.7)
Comorbidities
DM 15,891 (51.1) 371 (24.1) <0.001
MI 1,154 (3.7) 36 (2.3) 0.006
CHF 4,686 (15.1) 88 (5.7) <0.001
PVD 1,882 (6.1) 33 (2.1) <0.001
CVD 3,992 (12.8) 83 (5.4) <0.001
COPD 5,104 (16.4) 157 (10.2) <0.001
Peptic ulcer disease 4,557 (14.6) 201 (13.1) 0.092
Liver disease 3,354 (10.8) 149 (9.7) 0.187
Any cancer 1,949 (6.3) 28 (1.8) <0.001
Charlson comorbidity score 2.3 (1.9) 1.1 (1.4) <0.001
CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CVD = cerebrovascular dis
OBM = optimal balanced risk set matching, PD = peritoneal dialysis, PVD = peripheral vascular disea
∗
Before matching, the 2-sample t test is used; after matching, the paired t test is used.
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Before OBM, there were significant differences in age, dialysis
modality, insurance type (NHI vs Medical Aid), and comorbid-
ities between the groups. The mean patient age was 57.9 years in
the dialysis group and 41.8 years in the transplant group before
OBM (P<0.001). Patients undergoing PD had a greater
likelihood of undergoing KT than those who underwent HD
(26.6% vs 24.2%; P=0.033). The dialysis group had a larger
proportion of patients with Medical Aid coverage (14.0% vs
5.7%; P<0.001). In addition, the dialysis group had a greater
number of comorbidities such as diabetes, MI, CHF, PVD, CVD,
COPD, and any cancer.
After OBM, there were no differences in any of the variables,
including age, sex, the dialysis modalities, and comorbidities. The
mean patient age was 41.8 years in both groups (P=0.401).
Table 1 shows that the standardized difference value decreased
after OBM.3.2. Comparisons of all-cause mortality and
cardiovascular morbidities between the transplant and
matched control groups
All-cause mortality and MACE were compared between the
groups after performing OBM using the Gehan–Wilcoxon test.
The transplant group had a 2.5% crude all-cause mortality rate
(38 of 1532 patients) during the follow-up period (median
follow-up, 26.5 months), whereas the control group had a 19.2%
crude all-cause mortality rate (294 of 1532 patients). The
transplant group had a significantly better overall survival rate on
the Kaplan–Meier curve (P<0.001; Fig. 2A). In multivariate
analysis, the transplant group had better overall survival than the
control group after adjusting for confounding factors (hazard
ratio [HR], 0.15; 95% confidence interval [CI], 0.11–0.22; P<
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ease, DM = diabetes mellitus, HD = hemodialysis, ITT = intention to treat, MI =myocardial infarction,
se.
Figure 2. Comparison of cumulative survival rate in the control group and transplant group for overall survival rate (A) and major adverse cardiac events (MACE) (B)
after optimal balanced risk set matching. (A) Kaplan–Meier curves for the matched population including those in the control group (solid line) versus transplantation
group (dashed line); (B) Kaplan–Meier curves for MACE in the matched population (solid line) versus transplantation group (dashed line). MACE: incidence of
nonfatal myocardial infarction, hemorrhagic and ischemic stroke, coronary artery bypass graft surgery, or percutaneous coronary intervention.
Yoo et al. Medicine (2016) 95:33 www.md-journal.comTransplantation had the benefit of greater cardiovascular event-
free survival than maintenance dialysis, after adjusting for other
confounding variables. MACE occurred in 30 patients in the
transplant group and in 70 in the control group during the follow-
upperiod. Survival analysis showed that the transplantation group
had a better MACE-free survival rate (P<0.001; Fig. 2B). In Cox
regression analysis, the transplant group had better MACE-free
survival than the control group after adjusting for age, sex, the
dialysis modality, the health insurance type, and comorbidities
(HR, 0.49; 95% CI, 0.32–0.75; P<0.001) (Table 3).
3.3. Subgroup analyses according to baseline
characteristics after optimal balanced risk set matching
Thereafter, we performed a subgroup analysis to confirm the
clinical benefit of KT in the different subgroups. We divided theTable 2




Transplant (vs dialysis) 0.17 (0.12–0.24)
Age 1.06 (1.05–1.07)





National Health Insurance Reference








Peptic ulcer disease 1.18 (0.88–1.59)
Liver disease 1.06 (0.74–1.53)
Any cancer 3.48 (2.07–5.85)
CHF = congestive heart failure, CI = confidence interval, COPD = chronic obstructive pulmonary disease, C
intention to treat, MI = myocardial infarction, PD = peritoneal dialysis, PVD = peripheral vascular dise
∗
Adjusted for age, sex, the health security system, diabetes, MI, CHF, PVD, CVD, COPD, peptic ulcer
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study population into subgroups by age, the dialysis modality,
sex, the health insurance type, and comorbidities (Fig. 3A). When
multivariate analysis was performed for all-cause mortality by
age group, the transplant group had better overall survival than
the control group in all age groups. In elderly patients (≥60
years), KT improved overall survival (HR, 0.08; 95% CI,
0.03–0.21; P<0.001). In the other subgroups, transplantation
showed a greater survival benefit compared to the control after
adjusting for confounding factors. KT reduced all-cause
mortality in patients with DM (HR, 0.13; 95% CI, 0.08–0.23;
P<0.001). Interaction tests were marginal by age group.
Subgroup analysis for MACE-free survival (Fig. 3B) showed
that the transplant group had betterMACE-free survival than the
control group in most of the subgroups. Interaction tests were not
significant in any subgroup analysis.ivariate and multivariate analyses after optimal balanced risk set
Multivariate analysis
∗
P HR (95% CI) P
<0.001 0.15 (0.11–0.22) <0.001
<0.001 1.05 (1.04–1.06) <0.001
<0.001 1.06 (1.05–1.07) <0.001
0.007 0.66 (0.52–0.83) <0.001
<0.001 2.41 (1.66–3.51) <0.001
<0.001 2.44 (1.94–3.06) <0.001
<0.001 1.34 (0.83–2.16) 0.229
<0.001 1.47 (1.04–2.07) 0.031
0.208 0.85 (0.43–1.69) 0.644
<0.001 1.53 (1–2.35) 0.05
0.001 1.38 (1–1.9) 0.05
0.269 0.96 (0.71–1.31) 0.802
0.747 1 (0.69–1.45) 0.99
<0.001 4.73 (2.77–8.06) <0.001
VD = cerebrovascular disease, DM = diabetes mellitus, HD = hemodialysis, HR = hazard ratio, ITT =
ase.
disease, liver disease, and any cancer.
Table 3
Results from the Cox hazard model for major cardiovascular adverse events using univariate and multivariate analyses after optimal
balanced risk set matching.
Univariate analysis Multivariate analysis
∗
HR (95% CI) P HR (95% CI) P
Transplant (vs dialysis) 0.49 (0.32–0.75) 0.001 0.49 (0.32–0.75) 0.001
Age 1.04 (1.03–1.06) <0.001 1.03 (1.02–1.05) <0.001
Female sex (vs male sex) 1.06 (1.04–1.08) <0.001 1.05 (1.03–1.07) <0.001
Dialysis modality (ITT)
PD Reference
HD 0.95 (0.62–1.48) 0.833 0.9 (0.58–1.4) 0.638
Health security system
National Health Insurance Reference
Medical Aid 0.53 (0.17–1.68) 0.281 0.52 (0.16–1.66) 0.27
Comorbidities
DM 2.86 (1.93–4.24) <0.001 1.91 (1.26–2.9) 0.002
MI 4.21 (2.04–8.66) <0.001 2.17 (1.01–4.67) 0.046
CHF 1.26 (0.61–2.6) 0.527 0.9 (0.43–1.87) 0.777
PVD 1.62 (0.51–5.12) 0.409 1.13 (0.35–3.63) 0.841
CVD 2.84 (1.52–5.31) 0.001 1.86 (0.97–3.56) 0.06
COPD 0.59 (0.26–1.34) 0.207 0.45 (0.19–1.04) 0.063
Peptic ulcer disease 0.92 (0.51–1.64) 0.775 0.86 (0.48–1.57) 0.631
Liver disease 0.67 (0.37–1.21) 0.186 0.65 (0.28–1.49) 0.313
Any cancer 0 (0–.) 0.979 0 (0–.) 0.982
CHF = congestive heart failure, CI = confidence interval, COPD = chronic obstructive pulmonary disease, CVD = cerebrovascular disease, DM = diabetes mellitus, HD = hemodialysis, HR = hazard ratio, ITT =
intention to treat, MI = myocardial infarction, PD = peritoneal dialysis, PVD = peripheral vascular disease.
∗
Adjusted for age, sex, the health security system, diabetes, MI, CHF, PVD, CVD, COPD, peptic ulcer disease, liver disease, and any cancer.
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The additional analysis using data from the KONOS database
resulted in a much lower cumulative survival for the wait-listed
patients than both the living donor and deceased donor patients
with KT (Supplemental Fig. 1, http://links.lww.com/MD/B200).
There was no difference in the cumulative survival rates between
wait-listed patients and the matched control group (who did not
undergo transplantation) after PSM in the additional survival
analysis using the KONOS database and HIRA data (Supple-
mental Fig. 2, http://links.lww.com/MD/B200).
When comparing the incidence ofMACE (data not shown) and
the MACE-free survival rate between patients from the CRC for
ESRD database and matched control group in our study cohort
(HIRA data) (Supplemental Fig. 3, http://links.lww.com/MD/
B200), there was no difference in the cardiovascular outcomes
between the groups. The CRC for ESRD is a prospective cohort;
therefore, the patients have not been followed up to date. This
should be considered in the interpretation of our additional
analysis.4. Discussion
This is the first Asian national population-based study to evaluate
the direct clinical benefits of KT in patients with incident dialysis
using data from the national database of a public health
insurance program. The present study reports the characteristics
of all KTRs among patients with incident dialysis between 2005
and 2008 in Korea, and the results advocate a survival benefit of
KT. In contrast, Korean patients with incident dialysis who
underwent long-term dialysis had significantly more cardiovas-
cular events and higher all-cause mortality rates.6
Although KT has better clinical and socioeconomic benefits
than maintenance dialysis, these findings should be interpreted
with caution.[7] The benefits of KT may have resulted from
selection bias because patients undergoing maintenance dialysis
without KT tend to have a greater number of and more severe
comorbidities than those undergoing KT. It is difficult to conduct
a randomized control study comparing dialysis with transplan-
tation due to ethical issues. Moreover, several methodological
concerns about the comparison of maintenance dialysis and KT
have been raised.[7] To overcome differences in the baseline
characteristics, many other studies have used KT wait-listed
patients as study controls.[5,32–37]
As mentioned in Section 2.4, we could not directly compare
KTRs to patients on dialysis on the waiting list because HIRA
data do not indicate if patients are registered on a waiting list,
which could be considered a limitation of the study. Nonetheless,
we suggest that the optimal matched control group have similar
baseline characteristics to patients who are candidates for KT.
Considering the time-varying exposure that occurs in an
observational study setting, OBM was conducted in the present
study instead of conventional 2-group greedy matching.[22–24] Lu
et al presented a risk set matching method that uses a hazard of
receiving treatment. The time-varying cox hazard is as follows:
hmðtÞ ¼ h0ðtÞexpbTðXmðtÞÞ
It is used to estimate the hazard of being treated at a certain
time point for each patient.[22,23] If M is the number of patients
entered into the study, m=1, 2, 3, . . . , M, where patient m is
enrolled in the study at certain time point and may be treated at
any time or not at all. Xm(t) is the vector of covariates for patient
m at time t. The hazard for patient m at time t is hm(t).
Figure 3. Comparison of adjusted hazard ratios (HRs) for subgroups. (A) Adjusted HR of each subgroup for all-causemortality; (B) adjusted HR of each subgroup for
major adverse cardiac events (MACE). The adjusted covariates included age, sex, dialysismodality, health security system (HSS), and comorbidities (diabetesmellitus,
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease, peptic ulcer disease, liver
disease, and any type of cancer) for each subgroup (excluding own). (∗) The adjusted covariates included age, sex, dialysis modality, HSS, and Charlson comorbidity
score for each subgroup. MACE: incidence of nonfatal myocardial infarction, hemorrhagic and ischemic stroke, coronary artery bypass graft surgery, or percutaneous
coronary intervention. CI = confidence interval, COPD = chronic obstructive pulmonary disease, HR = hazard ratio, ITT = intention to treat.
Yoo et al. Medicine (2016) 95:33 www.md-journal.comBecause of the characteristics of the HIRA data, there are time-
fixed variables that consider baseline characteristics for all
covariates, except for the time point of the transplant, and newly
treated patients were matched with patients not yet treated by
using baseline covariates via the hazard of receiving the7
treatment. More details about the estimation of the propensity
score using a Cox proportional model are described by Lu
et al.[22,23]
In the present study, we also found that patients who
underwent PD required KT more often than patients on HD
Yoo et al. Medicine (2016) 95:33 Medicine(P=0.033) (Table 1). PD was recently suggested as a bridge
therapy before transplantation.[38–40] Schwenger et al reported
that pretransplant PD can reduce all-cause mortality by 10%
compared with pretransplant HD.[39] This may be one of the
reasons why we found poorer outcomes with maintenance PD
than with maintenance HD in our recent study.[16] Another
interesting finding of the present study was that patients with a
low socioeconomic status (SES) who were covered by Medical
Aid had a lower chance of undergoing KT. In addition, a low SES
was significantly associated with a 2.41-fold poorer overall
survival (Table 2). In studies regarding the association between
ethnic background and transplant outcomes conducted in
Western countries, household income disparity was a primary
confounder and/or mediator.[7,8,41] Although the association
between transplant outcomes and SES remains controversial,[7,8]
maintaining the HSS can affect the outcomes of transplant and
dialysis patients.[42]
A systematic review reported that KT reduces the risk of
death compared with patients on dialysis on the transplant
waiting list, with an HR of 0.16 to 0.73 in 94% of patients
according to the reviewed studies.[7] Our study showed that
transplantation improved overall survival and MACE-free
survival compared to dialysis without KT (HR, 0.15 and 0.49,
respectively). The benefits appear to be better than those
observed in previous studies. This can be explained by the less
severe comorbidities in the KTRs in Korea than those in
previous studies.[43] A high number of comorbidities, according
to the CCI, are closely correlated to posttransplant patient
survival. Wu et al reported that a CCI ≥5 increased the risk of
death by 2.88-fold.[43] In the present study, the mean CCI in the
transplant group was 1.1 and that in the dialysis group was 2.3,
whereas that in transplant recipients in the study by Wu et al
was 3.2. Moreover, the proportion of living-donor KTs in
Korea was higher than those in Western countries, although the
data were not available in this study.[17] In the present study,
diabetes was the most common comorbid condition (24.1%),
which was similar to the findings of Wu et al. Additionally,
diabetes, CVD, and any cancer were independent prognostic
factors for mortality. These findings are consistent with
previous studies that suggest that diabetes[44] or CVD[45,46]
worsened survival rates compared to those of patients without
comorbidities.
We assessed MACE-free survival, which included cardiovas-
cular events and cerebrovascular events (i.e., hemorrhagic and
ischemic stroke). In KTRs, the most common cause of death is
cardiovascular disease, accounting for 50% to 60% of such
cases.[47] Cardiovascular-related deaths commonly occur in
diabetic KTRs, whereas other causes such as tumors and
infections are associated with nondiabetic recipients.[48] The
deaths of approximately half of the cases with cardiovascular
disease were associated with CVD.[49] The main concern with
using claims data is how to define the incidence of MACE, and
the accuracy of diagnoses, especially for cardiovascular events
using claims data, has been addressed previously. The
prospective cohort in the Korean Heart Study validated an
acute MI diagnosis of 71.4% of patients using claims data.[50]
Previously, Park et al reported an 83% accuracy of diagnosing
CVDs using the claims data of 115,600 people.[51] Our study
showed better MACE-free survival compared with other studies
(HR, 0.49; CI, 0.32–0.75). Although several earlier studies have
confirmed the cardiovascular benefits of KT in various clinical
phenotypes, including diabetic nephropathy and lupus
nephritis,[7,52–57] they included few Asian patients. To our8
knowledge, the present study is the largest study to show the
cardiovascular benefit of KT in an East Asian population.
A subgroup analysis was additionally performed to clarify the
benefit of KT among high-risk KTRs. Patients in the transplant
group had better survival than those in the dialysis group among
all age groups. The posttransplant outcomes of elderly Asians are
not well known. We expect that results from stratification
analysis will aid in our understating of elderly KTRs. Moreover,
certain comorbidities such as diabetes affected the patients in
different ways due to ethnic heterogeneity. Although diabetes
remains a risk factor for poor outcomes in KTRs, there are no
reports in Asian KTRs with diabetic nephropathy.[48,52,58] The
present study showed that patients in the transplant group had
better overall survival and cardiovascular outcomes than those in
the dialysis group in most Asian subpopulations with high-risk
comorbidities, including old age and diabetes.
Our data had several limitations, including those mentioned
previously.[16] First, although immunological and nonimmuno-
logical factors can affect the clinical outcomes of kidney
transplant, we could not obtain data on immunological factors
such as the donor age, donor sex, donor type, human leukocyte
antigen mismatching, and immunosuppressive medication.
Second, graft outcomes were also unavailable. Third, the
observation period was relatively short. Finally, our data do
not include KT waiting-list information. To overcome this
limitation, we conducted several validation analyses.
In conclusion, among Korean patients with incident dialysis,
those who underwent KT showed significantly improved overall
survival and cardiovascular outcomes compared with those who
remained on dialysis. Hence, KT should be more actively
recommended in the Korean population.Acknowledgments
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